Regeneron and Sanofi Announce Mixed Results from Phase 3 AERIFY Trials for Itepekimab in COPD Patients

Regeneron and Sanofi's Phase 3 AERIFY-1 trial of itepekimab in former smokers with COPD met its primary endpoint, demonstrating a statistically significant 27% reduction in moderate to severe exacerbations compared to placebo; however, the AERIFY-2 trial did not meet its primary endpoint. While itepekimab was generally well-tolerated across both trials, the companies are evaluating the data and plan to consult with regulatory authorities regarding potential next steps, as well as continue development for other respiratory conditions. Institutional investors have decreased positions in $REGN stock, while analysts maintain a median price target of $850.

Analysis

Regeneron Pharmaceuticals and Sanofi reported mixed Phase 3 trial results for itepekimab in treating COPD in former smokers. The AERIFY-1 trial successfully met its primary endpoint, demonstrating a statistically significant 27% reduction in moderate to severe exacerbations compared to placebo, a clinically meaningful benefit. However, the second trial, AERIFY-2, failed to meet the same primary endpoint, despite observing some early benefits. Itepekimab was reported as generally well-tolerated across both trials, with safety profiles consistent with previous studies. The companies are currently evaluating the complete dataset and intend to consult with regulatory authorities on the path forward, while remaining committed to developing itepekimab for other respiratory conditions. Interpretation of the trial outcomes is complicated by a lower-than-prospectively-anticipated total number of exacerbations, potentially impacting statistical power, and the fact that enrollment largely occurred during the COVID-19 pandemic, raising questions about generalizability. Recent trading activity for REGN stock indicates a degree of caution: members of Congress executed 9 sales versus 1 purchase in the past six months. Institutional holdings data from Q1 2025 shows 771 investors decreased positions while 649 added, with significant reductions by JPMORGAN CHASE & CO (-19.8%) and CAPITAL WORLD INVESTORS (-30.2%), though firms like TWO SIGMA ADVISERS, LP and GOLDMAN SACHS GROUP INC initiated or increased substantial positions. Despite these mixed signals, Wall Street analysts have recently issued positive ratings, including two 'Buy' or equivalent ratings, and maintain a median price target of $850.0 for REGN.

Key Decisions for Investors

• Investors should exercise caution regarding itepekimab's prospects in COPD due to the conflicting Phase 3 trial results, awaiting further clarity from Regeneron and Sanofi's engagement with regulatory authorities and detailed data disclosures.
• Consider the potential impact of confounding factors, such as the COVID-19 pandemic's influence on trial enrollment and lower-than-expected exacerbation rates, on the regulatory view and commercial viability of itepekimab for COPD.
• Monitor institutional investor flows and congressional trading patterns for ongoing sentiment shifts, while balancing these against positive analyst ratings and the drug's continued development in other respiratory indications which may offer alternative value pathways.